AllDocs -> cancers

Patient Patient Surname : First Name : Address: NHS Number (New) Hospital No : Date of Birth D D M M Y Y Y Y / / Male Female Postcode : Telephone Number: Preferred Preferred Outpatient Hospital point of consultation Direct Access Gastroscopy Date of Decision to Refer by GP : D D M M Y Y Y Y Referring GP : Registered or Practice (code): Usual GP: GP GP FAX No. Number for confirmation of receipt : ? New onset of Dysphagia - food sticking on swallowing (any age) ? Dyspepsia combined with one or more of the following 'alarm' symptoms ( cancer very rare aged <45 years ): - Weight - anaemia - vomiting ? New onset of Dyspepsia ...

Metastatic progression of pancreatic cancer : Changes in antioxidant enzymes and cell growth Anne Lewis 5 , Juan Du 2 , Jingru Liu 2 , Justine M. Ritchie 3 , Larry W. Oberley 2,3,5 & Joseph J. Cullen 1,2,3,4,5 1 Departments of Surgery, 2 Radiation Oncology, 3 The Holden Comprehensive Cancer Center, 4 Veterans Affairs Medical Center, 5 University of Iowa College of Medicine, Iowa City, IA, USA Received 19 July 2005; accepted in revised form 8 November 2005 Key words: antioxidants, hypoxia, metastasis, pancreatic cancer , tumor growth Abstract Pancreatic cancer has a dismal prognosis due to the fact that patients present late when metastatic disease is already present. Previous studies have demonstrated ...

Chapter 29: Pancreatic cancer 281 Pancreatic cancer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

pancreatic cancer EUROPAC The European Registry of Hereditary Pancreatic Diseases EUROPAC Study Co-ordinator, Division of Surgery & Oncology, 5 th Floor UCD Block, Royal Liverpool University Hospital, Daulby Street, Liverpool, L69 3GA, United Kingdom Tel: +44 151 706 4184 europac@liv.ac.uk http://www.liv.ac.uk/surgery/europac.html Fax: +44 151 706 5826 EUROPAC Study Questionnaire of Familial Pancreatic Cancer To help us with our research, we would like to take some details about you and your medical history. Please answer as many questions as apply to you, and don’t worry if you don’t know all the answers. All this information will be treated in confidence, and we will not disclose any personal or identifying information to anyone without your permission. ...

Patient Information Pancreatic Cancer 1 of 16 Cambridge Surgical Hepato-Pancreato-Biliary Unit (Specialist Hepato-Pancreato-Biliary Unit – Eastern Region) Pancreatic cancer This leaflet has been written to help your understanding of pancreatic cancer . If you want to discuss any of part of your treatment or the information contained in this leaflet then please contact your Consultant or Specialist nurse involved in your care and they will be happy to answer any questions. The pancreas The pancreas is part of the digestive system. It is deep inside the belly, lying just in front of the spine. The large rounded section on the right-hand side of the body is called the head of the pancreas, the mid-section is known as the body of the pancreas and the narrow part on the left-hand side of the body is called the tail of the pancreas. The head of the ...

Pancreatic Cancer Pancreatic Cancer Resident Conference Resident Conference April 26, 2006 April 26, 2006 Erica R. H. Sutton, MD Erica R. H. Sutton, MD Page 2 Epidemiology Epidemiology Incidence Incidence In 2003: 30,700 new cases of pancreatic In 2003: 30,700 new cases of pancreatic adenocarcinoma were diagnosed adenocarcinoma were diagnosed Eighth most common malignancy, fourth Eighth most common malignancy, fourth leading cause of cancer related deaths leading cause of cancer related deaths Annual mortality equals annual incidence Annual mortality equals annual incidence Page 3 Epidemiology Epidemiology Risk Factors Risk Factors Smoking Smoking ...

Pancreatic Cancer a report by Rober t C Moesinger , MD Assistant Professor in the Section of Surgical Oncology in the Department of Surgery at the University of Maryland School of Medicine Pancreatic adenocarcinoma is one of the great challenges to oncologic physicians and surgeons.Statistics for the US are typical. In 2006, it is expected that there will be 33,730 new cases of pancreatic adenocarcinoma with 32,300 deaths. This corresponds to a survival rate of approximately 4%. Resectional surgery, followed by adjuvant therapy, has been the best hope for long-term survival, but the results are still disappointing. Among patients with resectable disease, median, three-year and five-year survival is approximately 25 months, 35% and 20%, respectively, with multimodality treatment. These survival data are from series with large numbers of patients and are probably ...

pancreatic Certificate of Conformance Material CAA, Pancreatic Catalog Number C2024 Scripps Part Number 90102 Lot Number 2220302 Source Human Fluids Form Clear liquid - Buffer: Phosphate Buffered Saline, 0.1% Sodium Azide, pH 7.4 ± 0.2 Storage 2°C to 8°C short term (up to 2 weeks); below -15°C long term. Avoid freeze-thaw cycles. Intended Use For Research Use or Further Manufacture Only. Not for Use in Diagnostic Procedures. Precaution Tested and found negative for HIV 1 & 2, Hepatitis B, and Hepatitis C. Although source materials have been tested for certain diseases, no test can absolutely assure the absence of all infectious agents. Therefore, this product ...

pancreatic Certificate of Conformance Material CAA, Pancreatic , part pure Catalog Number C2023 Scripps Part Number 90399 Lot Number 2220303 Source Human Fluids Form Clear liquid - Buffer: Phosphate Buffered Saline, 0.1% Sodium Azide, pH 7.4 ± 0.2 Storage 2°C to 8°C short term (up to 2 weeks); below -15°C long term. Avoid freeze-thaw cycles. Intended Use For Research Use or Further Manufacture Only. Not for Use in Diagnostic Procedures. Precaution Tested and found negative for HIV 1 & 2, Hepatitis B, and Hepatitis C. Although source materials have been tested for certain diseases, no test can absolutely assure the absence of all infectious agents. ...

Mesothelioma Articles A Study of MORAb-009 in Subjects With Pancreatic Cancer , Mesothelioma, or Certain Types of Ovarian or Lung Cancer This study is currently recruiting patients. Verified by Morphotek July 2006 Purpose The purpose of this study is to establish the safest doses of an investigational drug called MORAb-009 in subjects with pancreatic cancer , mesothelioma, or certain types of ovarian or lung cancer . MORAb-009 is a monoclonal antibody that is directed to an antigen on the surface of these cancers. MedlinePlus related topics: Lung Cancer ; Mesothelioma; Ovarian Cancer ; Pancreatic Cancer Study Type: Interventional Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study Official Title: A Study of the Safety, Tolerability, and Pharmacokinetics of MORAb-009, a Chimeric Monoclonal Antibody, in Subjects With ...

REVIEW Oncological problems in pancreatic cancer surgery Akimasa Nakao, Tsutomu Fujii, Hiroyuki Sugimoto, Naohito Kanazumi, Shuji Nomoto, Yasuhiro Kodera, Soichiro Inoue, Shin Takeda www.wjgnet.com Akimasa Nakao, Tsutomu Fujii, Hiroyuki Sugimoto, Naohito Kanazumi, Shuji Nomoto, Yasuhiro Kodera, Soichiro Inoue, Shin Takeda, Department of Surgery ?, Nagoya University Graduate School of Medicine, Nagoya, Japan Correspondence to: Professor Akimasa Nakao, MD, PhD, FACS, Professor and Chairman of Department of Surgery II, Nagoya University Graduate School of Medicine, 65 Tsurumai- cho, Showa-ku, Nagoya 466-8550, Japan. nakaoaki@med.nagoya-u.ac.jp Telephone: +81-52-7442232 Fax: +81-52-7442255 Received: 2006-02-03 Accepted: 2006-02-18 Abstract Despite the development of more sophisticated diagnos- tic techniques, pancreatic carcinoma has not yet been ...

pancreatic cancer 1581 Clinical Usefulness of CA19-9 as a Screening of an Pancreatic Cancer in Asymptomatic Population Ji-Hyang Kim, Jee-Eun Kim, Kyu Taek Lee Hee Jung Son, Kyung Mee Lee, Won Jae Chung Bong J. Choi, Yoon-Ho Choi & Chong H. Rhee Health Promotion Center, Samsung Medical Center Background (I) Prognosis for pancreatic cancer Generally poor Survival rate for resected pancreatic cancer much higher Importance of early detection Carbohydrate antigen 19-9 Tumor- associated, not a tumor specific antigen Synthesized by pancreatic and biliary ductular cells, gastric, colonic, endometrial, and salivary epithelia The best serum marker for ...

Cancer Therapy Vol 3, page 379 379 Cancer Therapy Vol 3, 379-382, 2005 Pancreatic cancer palliation using radiofrequency ablation. A new technique Case Report John D Spiliotis 1 , Anastasios C Datsis 1 , Panagiotis Chatzikostas 2 , Spyros P. Kekelos 1 , Athina N. Christopoulou 3 , Athanasios G. Rogdakis 1 , P Symeonides 2 1 Department of Surgery, “Hatzikostas” General Hospital of Messologi, Messologi, Greece 2 Department of Surgery, Nicosia General Hospital, Cyprus 3 Department of Internal Medicine, Section of Oncology, “St Andrews” General Hospital, Patras, Greece _ *Correspondence: John Spiliotis, M.D., Director of the Department of Surgery, “Hatzikostas” General Hospital of Messologi, 73 Pente ...

The 4 th Annual 5k Trail Walk/Run for Pancreatic Cancer September 30, 2006 TO BENEFIT PanCAN is a 501(c)(3) non-profit organization founded in 1999 by surviving family members of individuals who died of pancreatic cancer . PanCAN is the first, national advocacy organization for the pancreatic cancer community. The organization works to focus national attention on the need to find a cure for pancreatic cancer and provides public and professional education embracing the urgent need for more research, effective treatments, prevention programs and early detection methods. PanCAN’s unique grassroots network is comprised of community-based members across the United States, who volunteer their time to educate local communities about pancreatic cancer , create awareness about the disease and raise vital funds. For more information about ...

customer focus University of Alabama Research into Personalized Treatment for Brain and Pancreatic Cancer Using the TaqMan ® Low Density Arrays and the Applied Biosystems 7900HT Fast Real-Time PCR System Dr. Martin Johnson at the University of Alabama is a passionate researcher striving to improve treatment for patients with pancreatic and brain tumors, two of the most commonly known incurable cancers. Dr. Johnson explains, “Right now, the treatments we have were developed empirically, and for these two types of cancer , the approach has been disappointing. Median survival is one year or less, and there has been very little improvement in overall median survival.” Dr. Johnson hopes that combining information from the human genome project with microfluidic gene-expression analysis cards such as TaqMan ® Low Density Arrays will finally ...

ALTERNATIVE TREATMENTS FOR PANCREATIC CANCER Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support. Gonzalez NJ, Isaacs LL. Nutr Cancer 1999;33(2):117-24. The results of this study show that treatment consisting of high doses of pancreatic enzymes, detoxification procedures, organic diet and nutritional supplements, is associated with significant increased survival in patients with advanced pancreatic cancer (stage II through stage IV). The study was conducted on 11 patients with pancreatic cancer confirmed at histological analysis. They followed the aforementioned protocol while being at home, under the supervision of a physician. Survival rates were 81% at 1 year (9 patients), 45% at 2 years (5 patients), and 36% (4 patients) at 3 years. Two patients were currently being alive while the article was being ...

JOP. J Pancreas (Online) 2006; 7(4):332-336. JOP. Journal of the Pancreas - http://www.joplink.net - Vol. 7, No. 4 - July 2006. [ISSN 1590-8577] 332 EDITORIAL Serum Tumor Markers for Pancreatic Cancer : The Dawn of New Era? Takuji Okusaka 1 , Tesshi Yamada 2 , Masato Maekawa 3 1 Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital. Tokyo, Japan. 2 Chemotherapy Division and Cancer Proteomics Project, National Cancer Center Research Institute. Tokyo, Japan. 3 Department of Laboratory Medicine, Hamamatsu University School of Medicine. Hamamatsu, Japan Pancreatic cancer accounts for only 3% of all cancers, but it is the fifth leading cause of cancer death in both Western countries [1] and Japan [2]. The prognosis of patients with this disease is ...

JOP. J Pancreas (Online) 2006; 7(4):337-348. JOP. Journal of the Pancreas - http://www.joplink.net - Vol. 7, No. 4 - July 2006. [ISSN 1590-8577] 337 HIGHLIGHT ARTICLE - Slide show Pancreatic Cancer : Highlights from the 42 nd Annual Meeting of the American Society of Clinical Oncology, 2006 Muhammad Wasif Saif Yale University School of Medicine. New Haven, CT, USA ABSTRACT Despite advances in our understanding of the molecular and genetic basis of pancreatic cancer , the disease remains a clinical challenge. Gemcitabine, the standard chemotherapy for pancreatic cancer , offers modest improvement of tumor-related symptoms and marginal advantage of survival. New approaches, alone and in combination with gemcitabine, are being developed to combat this cancer . Combination ...

pancreatic cancer Preoperative (Neoadjuvant) Therapy Douglas B. Evans University of Texas M. D. Anderson Cancer Center June 17, 2003 Initial surgery is the correct treatment for the 10% to 20% without extra- pancreatic disease In the 80% with occult extra- pancreatic disease surgery delays systemic therapy 20% Additional concerns: angiogenesis / immune suppression Delivery of Neoadjuvant Therapy Surgical Oncology Diagnostic Imaging Gastroenterology Cytopathology Gastrointestinal Medical Oncology Radiation Oncology Nutrition Support Rationale for preop therapy Multimodality therapy superior to surgery alone Delayed recovery ...

Pancreatic Cancer Research at Garvan Pancreatic cancer (PC) is the fourth leading cause of cancer death in men and women in western societies including NSW, with a 5-year survival rate of less than 5% 1 . The latest Cancer Institute NSW statistics (2003) report that 580 people died of PC in NSW that year, compared to 896 dying of breast, 923 men of prostate, 1,072 of colon and 2,229 of lung cancer . The second leading group of cancer deaths is those with an unknown primary cancer site (1,256). Due to its inherent clinical characteristics, PC is likely to contribute a significantly greater proportion to these deaths than other cancers, hence the true proportion of deaths due to PC is likely to be underestimated. PC presents at an advanced stage, and as a result, only 10-20% of patients are suitable for surgical treatment at the time of presentation 1 . Chemotherapeutic agents ...

Page 2 Mortality trends in England; ICD9 (157), ICD10 (C25); File: Sepho 96-04 V2 Pancreatic cancer in England 1996 to 2004. Mortality trends Authors: Michael Goldacre, Marie Duncan, Paula Cook-Mozaffari, Matthew Davidson, Henry McGuiness, Daniel Meddings Published by: Unit of Health-Care Epidemiology, Oxford University, and South-East England Public Health Observatory, 2006 This document provides a profile of trends in mortality for pancreatic cancer in England. The period covered is January 1 1996 to December 31 2004. The data are analysed from mortality files supplied to the South East England Public Health Observatories (SEPHO) by the Office for National Statistics (ONS). Mortality rates were calculated for the condition certified as the underlying cause of death and for the disease certified as any mention on the death certificates. Age-specific ...

PANCREATIC CANCER Pancreatic cancer is the uncontrolled growth and spread of abnormal cells in the pancreas. Most pancreatic cancers begin in the ducts that carry pancreatic juices. An uncommon type of pancreatic cancer begins in the cells that produce insulin and other hormones. Risk Factors • People over the age of 60 • Family history - A family history of colon or ovarian cancer also increases the risk of pancreatic cancer . • Being male • Smoking • Diabetes • High fat diet • Chronic pancreatitis Symptoms • Pressure in the abdomen • Pain in the abdomen or back • Yellow skin and eyes, dark urine from jaundice • Weight loss • Nausea, loss of appetite, or weakness See your doctor if you ...

SUPPORTING THE NEEDS OF THE UNDERINSURED Patient Access Network Foundation PO Box 221858 Charlotte, NC 28222-1858 1.866.316.PANF (7263) www.patientaccessnetwork.org PANCREATIC CANCER Pancreatic cancer is one of the most serious of all cancers. It develops when malignant cells form in the tissues of the pancreas. Pancreatic cancer spreads rapidly and is seldom detected in its early stages. The most common treatment for pancreatic cancer is surgery, which involves the removal of all or a portion of the pancreas. If the cancer has spread and cannot be removed, palliative surgery may be done to relieve symptoms. Chemotherapy and radiation are typically used as follow up treatments to surgery. Private insurance and Medicare are the most common types of health coverage for patients with pancreatic cancer . Both have co- ...

Sun Q, Feng J, Wei XL, Zhang R, Dong SZ, Shen Q, Dong J, Li HD, Hu YH. Generation and characterization of a transgenic mouse model for pancreatic cancer . World J Gastroenterol 2006; 12(17): 2785-2788 http://www.wjgnet.com/1007-9327/12/2785.asp INTRODUCTION Pancreatic cancer is one of the most common malignant diseases threatening human life. The survival rate of pancreatic cancer patients is among the lowest in all kinds of cancer patients. The 1- 3- and 5-year survival rates have been reported to be 16%, 5% and 4%, respectively [1] . Early diagnosis and effective therapeutic intervention are essential to improve the situation. Animal models of pancreatic cancer should provide important tool for the identification of biomarkers for early detection and molecular mechanism studies of the pathological procession of pancreatic ...

PO Box 2345, Beijing 100023, China World J Gastroenterol 2006 May 14; 12(18): 2901-2907 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com © 2006 The WJG Press. All rights reserved. BASIC RESEARCH Down-regulation of survivin expression by small interfering RNA induces pancreatic cancer cell apoptosis and enhances its radiosensitivity Hai-Tao Guan, Xing-Huan Xue, Zhi-Jun Dai, Xi-Jing Wang, Ang Li, Zhao-Yin Qin www.wjgnet.com Hai-Tao Guan, Xing-Huan Xue, Zhi-Jun Dai, Xi-Jing Wang, Department of Oncosurgery, the Second affiliated Hospital of Xi’ an Jiaotong University Medical College, Xi’an 710004, Shaanxi Province, China Ang Li, Medical Research Center, Affiliated Stomatological Hospital of Xi’an Jiaotong University Medical College, Xi’an 710004, Shaanxi Province, China Zhao-Yin Qin, Department of General Surgery, ...

Friday 10 February 2006 A warts-and-all view of Avantogen's pancreatic cancer chances I f there's one thing guaranteed to excite attention in the biotech investment field, it's the result of a clinical trial. This analyst could talk until he was blue in the face about in vitro data, findings from animal model work, and even anecdotal evidence that a therapeutic approach works in people. However until a company is ready to report the outcome of a properly designed clinical study, only the aficionados will really be listening, and they generally aren't people who buy much biotech stock. That's why a company called Avantogen , ASX Code ACU, is of some interest to this analyst at the moment. If the name Avantogen doesn't ring a bell, you may know it by its pre-May 2005 name of Australian Cancer Technology, which also had the ACU ticker. When this analyst first looked ...

Capsaicin Shows Promise In Inhibiting Growth Of Pancreatic Cancer As of May 1/06 the evidence is in that capsaicin also is useful in coping with and even preventing prostae cancer . - CW ---------- Forwarded message ---------- From: Croft Woodruff < croftwoodruff@telus.net > Date: Apr 10, 2006 11:35 AM Subject: Capsaicin Shows Promise In Inhibiting Growth Of Pancreatic Cancer To: croft.woodruff@gmail.com Comment: Capsaicin stimulates digestion - particularly production of hydrochloric acid. The latter is essential to ionize minerals and hydrolyze protein fibre into chains of amino acids (peptides) that are then easily split into individual amino acids that are essential for the transport of minerals (as neutral amino acid mineral chelates) from the small intestine into the blood. Lack of HCL stimulates over production of the pancreatic enzyme trypsin to the point ...

Surgical Management of Early-Stage Pancreatic Cancer Emmanuel E. Zervos, MD, Alexander S. Rosemurgy, MD, Osama Al-Saif, MD, and Alan J. Durkin, MD Background: Pancreatic cancer remains a difficult disease to treat. Diagnosis at an early stage may allow curative treatment with resection. In the past, the mortality associated with surgical treatment of pancreatic carcinoma was prohibitive but mortality associated with resection is now commensurate with all other major oncologic resections. Thus, the focus of surgical management has shifted to address several issues: the diagnosis and evaluation of patients with suspected pancreatic cancer , the role of preoperative endobiliary stenting, the role of laparoscopy, the extent of resection, the role of adjuvant and neoadjuvant treatment, and the role of specialized centers in treating the disease. Methods: The current literature is reviewed ...

GENE MODIFIED CELL LINES AS VACCINE FOR PANCREATIC CANCER : THE JOHNS HOPKINS EXPERIENCE Dan Laheru, Barbara Biedrzycki, Ross Abrams, John Cameron, Kristen Hege, Ralph Hruban, Keith Lillemoe, Beth Onners, Sara Solt, Irena Tartakovsky, Charles Yeo, Elizabeth Jaffee The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD New therapies are urgently needed for all stages of pancreatic adenocarcinoma. We have developed a novel gene-modified whole cell allogeneic vaccine strategy for activating antitumor immune responses. Pre-clinical models have demonstrated that tumor cells genetically modified to secrete the cytokine granulocyte/macrophage-colony stimulating factor (GM-CSF) can generate potent, T cell- dependent, systemic antitumor immunity. We tested in our initial phase I trial two allogeneic GM-CSF secreting pancreatic vaccine cell lines integrated with chemoradiotherapy in 14 patients ...